Adolore BioTherapeutics
Adolore BioTherapeutics is developing a novel neuromodulation platform centered on a proprietary gene therapy that delivers a novel CA8 therapeutic peptide directly inside targeted neurons and nerve fibers. Their lead programs target chronic osteoarthritis knee pain and the rare condition erythromelalgia, with a broader pipeline extending into epilepsy, hearing loss, and ophthalmology. The company's mission is to create safe, effective, and accessible non-opioid therapies to combat the opioid crisis by providing highly localized, disease-modifying treatments.
Private Company
Funding information not available
AI Company Overview
Adolore BioTherapeutics is developing a novel neuromodulation platform centered on a proprietary gene therapy that delivers a novel CA8 therapeutic peptide directly inside targeted neurons and nerve fibers. Their lead programs target chronic osteoarthritis knee pain and the rare condition erythromelalgia, with a broader pipeline extending into epilepsy, hearing loss, and ophthalmology. The company's mission is to create safe, effective, and accessible non-opioid therapies to combat the opioid crisis by providing highly localized, disease-modifying treatments.
Technology Platform
A proprietary gene therapy platform combining a novel intracellular neuromodulating CA8 peptide with a locally-administered, non-replicating viral vector designed for targeted delivery to specific neurons and nerve fibers.
Opportunities
Risk Factors
Competitive Landscape
Adolore competes in the crowded chronic pain space against large pharma's NSAIDs and biologics, as well as other neuromodulation approaches. Its key differentiator is the combination of a novel intracellular peptide (CA8) with local gene therapy delivery, aiming for precise, durable, disease-modifying effects without systemic opioid side effects. In erythromelalgia, it faces emerging competition from Nav1.7 channel blockers.